CO2020000374A2 - Proceso mejorado para preparar derivados de aminopirimidina - Google Patents

Proceso mejorado para preparar derivados de aminopirimidina

Info

Publication number
CO2020000374A2
CO2020000374A2 CONC2020/0000374A CO2020000374A CO2020000374A2 CO 2020000374 A2 CO2020000374 A2 CO 2020000374A2 CO 2020000374 A CO2020000374 A CO 2020000374A CO 2020000374 A2 CO2020000374 A2 CO 2020000374A2
Authority
CO
Colombia
Prior art keywords
preparing
improved process
aminopyrimidine derivatives
protein kinases
present
Prior art date
Application number
CONC2020/0000374A
Other languages
English (en)
Inventor
Sang Ho Oh
Seong Ran Lee
Woo Seob Shin
Hyun Ju
Su Min Park
Ja-Heouk Khoo
Jong-Chul Lim
Dae-Gyu Park
Yoon-Ah Hwang
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65040211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2020000374(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of CO2020000374A2 publication Critical patent/CO2020000374A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22—Tin compounds
    • C07F7/2284—Compounds with one or more Sn-N linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)

Abstract

La presente invención proporciona un proceso mejorado para preparar un derivado de aminopirimidina o sal farmacéuticamente aceptable de este que tienen una actividad inhibidora selectiva contra proteínas quinasas, especialmente contra las proteínas quinasas para receptores del factor de crecimiento epidérmico mutantes. Además, la presente invención proporciona intermedios novedosos útiles para el proceso y procesos para prepararlos.
CONC2020/0000374A 2017-07-28 2020-01-15 Proceso mejorado para preparar derivados de aminopirimidina CO2020000374A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170096212 2017-07-28
PCT/KR2018/008379 WO2019022485A1 (en) 2017-07-28 2018-07-25 IMPROVED PROCESS FOR THE PREPARATION OF AMINOPYRIMIDINE DERIVATIVES

Publications (1)

Publication Number Publication Date
CO2020000374A2 true CO2020000374A2 (es) 2020-05-05

Family

ID=65040211

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0000374A CO2020000374A2 (es) 2017-07-28 2020-01-15 Proceso mejorado para preparar derivados de aminopirimidina

Country Status (31)

Country Link
US (4) US10889578B2 (es)
EP (1) EP3658552B1 (es)
JP (2) JP7228562B2 (es)
KR (1) KR20190013553A (es)
CN (2) CN111315742B (es)
AU (2) AU2018308038B2 (es)
BR (1) BR112020001278A2 (es)
CA (1) CA3070069C (es)
CO (1) CO2020000374A2 (es)
DK (1) DK3658552T3 (es)
EA (1) EA202090383A1 (es)
ES (1) ES2962961T3 (es)
FI (1) FI3658552T3 (es)
HR (1) HRP20231191T1 (es)
HU (1) HUE063533T2 (es)
IL (2) IL271973B (es)
LT (1) LT3658552T (es)
MA (1) MA49700B1 (es)
MD (1) MD3658552T2 (es)
MX (1) MX2022008743A (es)
NZ (1) NZ761156A (es)
PH (1) PH12020500059A1 (es)
PL (1) PL3658552T3 (es)
PT (1) PT3658552T (es)
RS (1) RS64654B1 (es)
SA (1) SA520411112B1 (es)
SG (1) SG11201913517UA (es)
SI (1) SI3658552T1 (es)
UA (1) UA125317C2 (es)
WO (1) WO2019022485A1 (es)
ZA (1) ZA202001250B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20231191T1 (hr) * 2017-07-28 2024-02-02 Yuhan Corporation Postupak za proizvodnju n-(5-((4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoksi-2-morfolinofenil)akrilamida putem reakcije odgovarajućeg amina s 3-halo-propionilkloridom
WO2020230091A1 (en) 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
US11850248B2 (en) * 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
US11780824B2 (en) * 2020-12-16 2023-10-10 Scinopharm Taiwan, Ltd. Process for preparing osimertinib or a salt thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
RU2309150C2 (ru) 2001-11-27 2007-10-27 Уайт Холдингз Корпорейшн 3-цианохинолины в качестве ингибиторов egf-r и her2 киназ
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
KR20070085433A (ko) 2004-11-24 2007-08-27 노파르티스 아게 Ｊａｋ 저해제들과 ｂｃｒ-ａｂｌ, ｆｌｔ-3, ｆａｋ 또는ｒａｆ 키나제 저해제들 중 하나 이상의 조합물
US20060270600A1 (en) 2005-05-26 2006-11-30 Eisuke Mekada Anti-cancer agents
TW200736232A (en) 2006-01-26 2007-10-01 Astrazeneca Ab Pyrimidine derivatives
CL2007003049A1 (es) 2006-10-23 2008-05-16 Cephalon Inc Pharmacopeia Drug Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.
TW200840581A (en) 2007-02-28 2008-10-16 Astrazeneca Ab Novel pyrimidine derivatives
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
KR101892989B1 (ko) * 2008-06-27 2018-08-30 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
CA2777762A1 (en) 2009-10-12 2011-04-21 Myrexis, Inc. Amino - pyrimidine compounds as inhibitors of tbk1 and/or ikk epsilon
CN102811619B (zh) 2009-11-13 2015-04-22 金纳斯克公司 激酶抑制剂
ES2629170T3 (es) 2009-12-04 2017-08-07 Senhwa Biosciences, Inc. Pirazolopirimidinas y heterociclos relacionados como inhibidores de CK2
EA022623B1 (ru) 2010-10-06 2016-02-29 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Производные бензимидазола в качестве ингибиторов pi3-киназ
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
RU2591195C2 (ru) 2010-12-13 2016-07-10 Эррэй Биофарма Инк. Замещенные n-(1h-индазол-4-ил) имидазол [1,2-а]пиридин-3- карбоксамидные соединения в качестве ингибиторов рецепторной тирозинкиназы iii типа
ES2900230T3 (es) 2011-07-27 2022-03-16 Astrazeneca Ab Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
US20130165472A1 (en) 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP3617213A1 (en) 2011-12-30 2020-03-04 Hanmi Pharm. Co., Ltd. Thieno[3,2-d]pyrimidine derivatives having inhibitory activity for protein kinases
CN104860891B (zh) 2014-02-25 2017-06-30 上海海雁医药科技有限公司 芳氨基嘧啶类化合物及其应用以及由其制备的药物组合物和药用组合物
EP3143015B1 (en) 2014-05-13 2019-02-20 ARIAD Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CN111875585B (zh) 2014-06-12 2023-06-23 上海艾力斯医药科技股份有限公司 一类激酶抑制剂
SG11201701960XA (en) * 2014-10-13 2017-04-27 Yuhan Corp Compounds and compositions for modulating egfr mutant kinase activities
CN104788427B (zh) 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
AR102263A1 (es) 2015-10-14 2017-02-15 Yuhan Corp Compuestos y composiciones para la modulación de las actividades quinasa del receptor de egf mutante
DE102017212159A1 (de) 2017-07-14 2019-01-17 Krones Aktiengesellschaft Verfahren und Vorrichtung zur Handhabung von Stückgütern, Artikeln und/oder Gebinden
PL3658547T3 (pl) 2017-07-28 2024-01-03 Yuhan Corporation Sposób wytwarzania n-(5-(4-(4-formylo-3-fenylo-1h-pirazol-1-ilo)pirymidyn-2-yloamino)-4-metoksy-2-morfolinofenylo)akrylamidu
HRP20231191T1 (hr) * 2017-07-28 2024-02-02 Yuhan Corporation Postupak za proizvodnju n-(5-((4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoksi-2-morfolinofenil)akrilamida putem reakcije odgovarajućeg amina s 3-halo-propionilkloridom
CN108826170A (zh) 2018-06-26 2018-11-16 深圳市远润欣电子有限公司 局部全般照明的模式、控制方法及台灯

Also Published As

Publication number Publication date
CN111315742A (zh) 2020-06-19
PT3658552T (pt) 2023-11-03
CN111315742B (zh) 2023-09-01
RS64654B1 (sr) 2023-10-31
EP3658552A1 (en) 2020-06-03
AU2018308038B2 (en) 2022-02-03
PL3658552T3 (pl) 2024-02-19
US20220281861A1 (en) 2022-09-08
IL271973B (en) 2022-08-01
AU2018308038A1 (en) 2020-01-30
SG11201913517UA (en) 2020-02-27
JP2023027091A (ja) 2023-03-01
MA49700A (fr) 2021-03-17
WO2019022485A1 (en) 2019-01-31
JP7228562B2 (ja) 2023-02-24
ZA202001250B (en) 2023-04-26
AU2022202936A1 (en) 2022-05-26
DK3658552T3 (da) 2023-11-20
EA202090383A1 (ru) 2020-06-15
EP3658552A4 (en) 2021-06-23
IL292429B1 (en) 2023-05-01
SA520411112B1 (ar) 2022-02-21
HRP20231191T1 (hr) 2024-02-02
IL271973A (en) 2020-02-27
MD3658552T2 (ro) 2024-02-29
FI3658552T3 (fi) 2023-11-16
NZ761156A (en) 2024-01-26
US20200165236A1 (en) 2020-05-28
MX2022008743A (es) 2023-02-02
CN116987112A (zh) 2023-11-03
SI3658552T1 (sl) 2023-11-30
JP2020528440A (ja) 2020-09-24
PH12020500059A1 (en) 2020-09-28
BR112020001278A2 (pt) 2020-07-21
US20230312545A1 (en) 2023-10-05
US20210269427A1 (en) 2021-09-02
CA3070069C (en) 2024-02-20
IL292429B2 (en) 2023-09-01
MA49700B1 (fr) 2023-09-27
US10889578B2 (en) 2021-01-12
UA125317C2 (uk) 2022-02-16
CA3070069A1 (en) 2019-01-31
US11286253B2 (en) 2022-03-29
ES2962961T3 (es) 2024-03-22
EP3658552B1 (en) 2023-09-13
HUE063533T2 (hu) 2024-01-28
IL292429A (en) 2022-06-01
KR20190013553A (ko) 2019-02-11
US11708362B2 (en) 2023-07-25
LT3658552T (lt) 2023-11-27
AU2022202936B2 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
CO2020000374A2 (es) Proceso mejorado para preparar derivados de aminopirimidina
ZA202202097B (en) Amino pyrimidine ssao inhibitors
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
CL2016001895A1 (es) Compuestos
EP4006016A3 (en) Probes for imaging huntingtin protein
PH12017550004B1 (en) Heterocyclic derivatives and use thereof
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2015015168A (es) Derivados heterociclicos y sus usos.
CO2020000371A2 (es) Intermedios útiles para la síntesis de un inhibidor selectivo contra proteín cinasas y procesos para preparar los mismos
MX2021005891A (es) Sondas para la proyeccion de imagen de la proteina huntingtina.
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
MX2017002705A (es) Sondas para la proyección de imagen de la proteína huntingtina.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2018013573A (es) Ciertos inhibidores de la proteína cinasa.
CO2020000595A2 (es) Intermedios novedosos útiles para la síntesis de derivados de aminopirimidina, proceso para prepararlos, y proceso para preparar derivados de aminopirimidina usando estos
WO2015179823A8 (en) Lung localized inhibitors of alpha(v)beta 6
MX2016016491A (es) Derivados de o-alquil-bencilidenguanidina y uso terapeutico para el tratamiento de trastornos asociados con acumulacion de proteinas mal plegadas.
WO2018211324A8 (en) Prodrugs for the treatment of disease
WO2019014322A8 (en) KINASE INHIBITORS FOR THE TREATMENT OF DISEASES
CO2021003412A2 (es) Nuevos derivados de tiazol y sus sales farmacéuticamente aceptables
WO2018211323A8 (en) Heterocyclic compounds for the treatment of disease
EP3681497A4 (en) INHIBITION OF PROTEIN KINASE C TO EXTEND TISSUE PLASMINOGEN ACTIVATOR TREATMENT IN ISCHEMIC DISEASES
WO2016089062A3 (en) Heterocyclic derivatives and use thereof
CL2015003780A1 (es) Compuestos derivados pirimido-isoquinolin-quinonas, sus sales, isomeros, tautomeros farmacéuticas aceptables; composiciones farmáceuticas; procedimiento de preparación; y su uso en el tratamiento de enfermedades bacterianas y bacterianas multirresistentes.